Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19

Summary

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.

Timeline

Start

2022-12-19

Primary completion

2023-05-31

Completion

2023-07-14

Outcome

Met primary endpoint

paper Patients who received GST-HG171 plus Ritonavir showed shortened median time to sustained recovery of clinical symptoms compared to the placebo group PMID 38618202 ↗

paper 13.0 days [95.45% confidence interval 12.0-15.0] vs. 15.0 days [14.0-15.0], P = 0.031 PMID 38618202 ↗

Publications

• Lu H, Zhang G, Mao J, Chen X, Zhan Y, Lin L, Zhang T, Tang Y, Lin F, Zhu F, Lin Y, Zeng Y, Zhang K, Yuan W, Liang Z, Sun R, Huo L, Hu P, Lin Y, Zhuang X, Wei Z, Chen X, Yan W, Yan X, Mu L, Lin Z, Tu X, Tan H, Huang F, Hu Z, Li H, Li G, Fu H, Yang Z, Chen X, Wang FS, Zhong N. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial. EClinicalMedicine. 2024 Apr 10;71:102582. doi: 10.1016/j.eclinm.2024.102582. eCollection 2024 May.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GST-HG171	Small molecule	150 mg	Oral
Background	Ritonavir	Other / unclassified	100 mg	Oral

Indications